Trial Profile
Phase I proof-of-concept trial of savolitinib in combination with durvalumab [MEDI-4736] as a first-line treatment in patients with papillary renal cell carcinoma
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Savolitinib (Primary) ; Durvalumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Proof of concept
- 15 Oct 2015 New trial record
- 13 Oct 2015 According to a Chi-Med media release, this trial is expected to be initiated by end the of 2015.